AU2014247941C1 - Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity - Google Patents
Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity Download PDFInfo
- Publication number
- AU2014247941C1 AU2014247941C1 AU2014247941A AU2014247941A AU2014247941C1 AU 2014247941 C1 AU2014247941 C1 AU 2014247941C1 AU 2014247941 A AU2014247941 A AU 2014247941A AU 2014247941 A AU2014247941 A AU 2014247941A AU 2014247941 C1 AU2014247941 C1 AU 2014247941C1
- Authority
- AU
- Australia
- Prior art keywords
- benzimidazol
- benzimidazolylphenyl
- diene
- androsta
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 131
- 108010080146 androgen receptors Proteins 0.000 title claims abstract description 56
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 33
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 32
- 102000001307 androgen receptors Human genes 0.000 title claims description 54
- 230000003828 downregulation Effects 0.000 title abstract description 8
- 230000000694 effects Effects 0.000 title description 29
- 230000003389 potentiating effect Effects 0.000 title description 15
- 230000003637 steroidlike Effects 0.000 title description 14
- 239000003098 androgen Substances 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 68
- MDHIWBNJNHUBJL-VMXHOPILSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC=C21 MDHIWBNJNHUBJL-VMXHOPILSA-N 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000000593 degrading effect Effects 0.000 claims description 5
- -1 steroid compounds Chemical class 0.000 abstract description 67
- 238000011282 treatment Methods 0.000 abstract description 22
- 239000003795 chemical substances by application Substances 0.000 abstract description 20
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract description 6
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 5
- 102100032187 Androgen receptor Human genes 0.000 abstract description 4
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 206010005003 Bladder cancer Diseases 0.000 abstract description 3
- 206010006187 Breast cancer Diseases 0.000 abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 3
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 abstract description 3
- 208000027747 Kennedy disease Diseases 0.000 abstract description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 3
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 3
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract description 3
- 230000005012 migration Effects 0.000 abstract description 3
- 238000013508 migration Methods 0.000 abstract description 3
- 201000002528 pancreatic cancer Diseases 0.000 abstract description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 3
- 201000005112 urinary bladder cancer Diseases 0.000 abstract description 3
- 201000004384 Alopecia Diseases 0.000 abstract description 2
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 abstract description 2
- 206010068168 androgenetic alopecia Diseases 0.000 abstract description 2
- 201000002996 androgenic alopecia Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 198
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 89
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 64
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 63
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 54
- 239000000203 mixture Substances 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 238000005481 NMR spectroscopy Methods 0.000 description 48
- 235000019439 ethyl acetate Nutrition 0.000 description 44
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 43
- PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 description 39
- 238000003818 flash chromatography Methods 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 27
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 229920002554 vinyl polymer Polymers 0.000 description 23
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 239000003208 petroleum Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 101150041968 CDC13 gene Proteins 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 13
- 235000010290 biphenyl Nutrition 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 12
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 229950003400 galeterone Drugs 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 239000004305 biphenyl Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 229960003399 estrone Drugs 0.000 description 9
- 150000002460 imidazoles Chemical class 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 229960004671 enzalutamide Drugs 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 7
- 230000002280 anti-androgenic effect Effects 0.000 description 7
- 230000002222 downregulating effect Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 6
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 6
- 239000000051 antiandrogen Substances 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- 229960000853 abiraterone Drugs 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 150000002790 naphthalenes Chemical class 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 4
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 4
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001443 androstenes Chemical class 0.000 description 4
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 3
- FFCSRWGYGMRBGD-UHFFFAOYSA-N 3-iodoaniline Chemical compound NC1=CC=CC(I)=C1 FFCSRWGYGMRBGD-UHFFFAOYSA-N 0.000 description 3
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical group OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 3
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 3
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000003973 alkyl amines Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000004074 biphenyls Chemical class 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- CASUWPDYGGAUQV-UHFFFAOYSA-M potassium;methanol;hydroxide Chemical compound [OH-].[K+].OC CASUWPDYGGAUQV-UHFFFAOYSA-M 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- WFWQWTPAPNEOFE-UHFFFAOYSA-N (3-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(O)=C1 WFWQWTPAPNEOFE-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- CTPUUDQIXKUAMO-UHFFFAOYSA-N 1-bromo-3-iodobenzene Chemical compound BrC1=CC=CC(I)=C1 CTPUUDQIXKUAMO-UHFFFAOYSA-N 0.000 description 2
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- DBVFWZMQJQMJCB-UHFFFAOYSA-N 3-boronobenzoic acid Chemical compound OB(O)C1=CC=CC(C(O)=O)=C1 DBVFWZMQJQMJCB-UHFFFAOYSA-N 0.000 description 2
- PKLOLYRHBHWFSR-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]phenol Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC=C(C=C2)O PKLOLYRHBHWFSR-UHFFFAOYSA-N 0.000 description 2
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940124766 Cyp17 inhibitor Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 238000007341 Heck reaction Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 229910020667 PBr3 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004103 abiraterone acetate Drugs 0.000 description 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- IATKKATWPOVYCC-VMXHOPILSA-N androstene group Chemical group [C@@H]12CCC[C@@]1(C)CC[C@H]1[C@H]2CCC2=CCCC[C@]12C IATKKATWPOVYCC-VMXHOPILSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KLTWGRFNJPLFDA-UHFFFAOYSA-N benzimidazolide Chemical group C1=CC=C2[N-]C=NC2=C1 KLTWGRFNJPLFDA-UHFFFAOYSA-N 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000006344 deformylation reaction Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical group COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- JPVZXDNGPVCEIB-UHFFFAOYSA-N n-[3-(1h-benzimidazol-2-yl)phenyl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC(C=2NC3=CC=CC=C3N=2)=C1 JPVZXDNGPVCEIB-UHFFFAOYSA-N 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical compound [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- IPSRUMUXEPMQCS-UHFFFAOYSA-N (1-methoxycyclohexa-2,4-dien-1-yl)boronic acid Chemical compound COC1(B(O)O)CC=CC=C1 IPSRUMUXEPMQCS-UHFFFAOYSA-N 0.000 description 1
- YDMRDHQUQIVWBE-UHFFFAOYSA-N (2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1O YDMRDHQUQIVWBE-UHFFFAOYSA-N 0.000 description 1
- GZFAVYWCPSMLCM-UHFFFAOYSA-N (6-methoxynaphthalen-2-yl)boronic acid Chemical compound C1=C(B(O)O)C=CC2=CC(OC)=CC=C21 GZFAVYWCPSMLCM-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- MXVLMYZRJAHEIS-UHFFFAOYSA-N 1-(2-phenylphenyl)naphthalene Chemical class C1=CC=CC=C1C1=CC=CC=C1C1=CC=CC2=CC=CC=C12 MXVLMYZRJAHEIS-UHFFFAOYSA-N 0.000 description 1
- MYBHMJDABCMHHR-UHFFFAOYSA-N 1-[2-[4-[3-(2H-tetrazol-5-yl)phenyl]phenyl]ethyl]benzimidazole Chemical compound N1N=NN=C1C=1C=C(C=CC1)C1=CC=C(C=C1)CCN1C=NC2=C1C=CC=C2 MYBHMJDABCMHHR-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- LSEFXLGTUCVBPE-UHFFFAOYSA-N 1h-imidazol-2-ylcarbamic acid Chemical class OC(=O)NC1=NC=CN1 LSEFXLGTUCVBPE-UHFFFAOYSA-N 0.000 description 1
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 1
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 1
- PQGCOTPHAQSVNB-UHFFFAOYSA-N 2-[3-[6-(1H-imidazol-2-yl)-7-methoxynaphthalen-2-yl]phenyl]-1H-benzimidazole Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)C=2C=C1C=C(C(=CC1=CC2)C=2NC=CN2)OC PQGCOTPHAQSVNB-UHFFFAOYSA-N 0.000 description 1
- AKYNMSZEWPONLN-UHFFFAOYSA-N 2-[6-(4-methoxyphenyl)naphthalen-1-yl]-1H-benzimidazole Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC=C(C=C2)OC AKYNMSZEWPONLN-UHFFFAOYSA-N 0.000 description 1
- XFQVZFJARGYKSA-UHFFFAOYSA-N 2-[6-[4-(1H-imidazol-2-yl)-3-methoxyphenyl]naphthalen-1-yl]-1H-benzimidazole Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC(=C(C=C2)C=2NC=CN2)OC XFQVZFJARGYKSA-UHFFFAOYSA-N 0.000 description 1
- KXBZOEKHHOAMPF-UHFFFAOYSA-N 2-[6-[4-(1H-imidazol-2-yl)phenyl]naphthalen-1-yl]-1H-benzimidazole Chemical compound N1C(=NC=C1)C1=CC=C(C=C1)C=1C=C2C=CC=C(C2=CC1)C=1NC2=C(N1)C=CC=C2 KXBZOEKHHOAMPF-UHFFFAOYSA-N 0.000 description 1
- YWTBYFOBDLIVAX-UHFFFAOYSA-N 2-[[3-(1H-benzimidazol-2-yl)phenyl]methyl]-6-(1H-imidazol-2-yl)-3-methyl-3,4-dihydro-1H-isoquinoline Chemical compound N1C(=NC=C1)C=1C=C2CC(N(CC2=CC1)CC=1C=C(C=CC1)C=1NC2=C(N1)C=CC=C2)C YWTBYFOBDLIVAX-UHFFFAOYSA-N 0.000 description 1
- ZLGLCPWVFCRKKH-UHFFFAOYSA-N 2-[[4-(3-methoxyphenyl)phenyl]methyl]-1H-benzimidazole Chemical compound COc1cccc(c1)-c1ccc(Cc2nc3ccccc3[nH]2)cc1 ZLGLCPWVFCRKKH-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- BAQXGQCFFKMGOQ-UHFFFAOYSA-N 3-(iodomethyl)pyridine;hydroiodide Chemical compound I.ICC1=CC=CN=C1 BAQXGQCFFKMGOQ-UHFFFAOYSA-N 0.000 description 1
- URUXAVOZGRPALR-UHFFFAOYSA-N 3-[4-(1H-benzimidazol-2-ylmethyl)phenyl]phenol Chemical compound Oc1cccc(c1)-c1ccc(Cc2nc3ccccc3[nH]2)cc1 URUXAVOZGRPALR-UHFFFAOYSA-N 0.000 description 1
- OUJNOEQTRYDDLE-UHFFFAOYSA-N 3-[4-[2-(1H-benzimidazol-2-yl)ethyl]phenyl]benzoic acid Chemical compound OC(=O)c1cccc(c1)-c1ccc(CCc2nc3ccccc3[nH]2)cc1 OUJNOEQTRYDDLE-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- VAJUUDUWDNCECT-UHFFFAOYSA-N 4-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=NC=C1 VAJUUDUWDNCECT-UHFFFAOYSA-N 0.000 description 1
- AYHAKQHYADHDHD-UHFFFAOYSA-N 4-[4-[2-(1H-benzimidazol-2-yl)ethyl]phenyl]-2-cyanobenzoic acid Chemical compound OC(=O)c1ccc(cc1C#N)-c1ccc(CCc2nc3ccccc3[nH]2)cc1 AYHAKQHYADHDHD-UHFFFAOYSA-N 0.000 description 1
- CGYCOGYBMJEFFU-UHFFFAOYSA-N 4-[5-(1H-benzimidazol-2-yl)naphthalen-2-yl]-2-methoxybenzoic acid Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC(=C(C(=O)O)C=C2)OC CGYCOGYBMJEFFU-UHFFFAOYSA-N 0.000 description 1
- HWIOEXJOMZQJCP-UHFFFAOYSA-N 4-[5-(1H-benzimidazol-2-yl)naphthalen-2-yl]-2-methoxybenzonitrile Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC(=C(C=C2)C#N)OC HWIOEXJOMZQJCP-UHFFFAOYSA-N 0.000 description 1
- SUFUUJRDSCSWQP-UHFFFAOYSA-N 4-[5-(1H-benzimidazol-2-yl)naphthalen-2-yl]-2-methoxyphenol Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC(=C(C=C2)O)OC SUFUUJRDSCSWQP-UHFFFAOYSA-N 0.000 description 1
- OXHXANFEKLMCAK-UHFFFAOYSA-N 4-[5-(1H-benzimidazol-2-yl)naphthalen-2-yl]benzoic acid Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC=C(C(=O)O)C=C2 OXHXANFEKLMCAK-UHFFFAOYSA-N 0.000 description 1
- RHZYHLAACTZRAU-UHFFFAOYSA-N 4-[5-(1H-benzimidazol-2-yl)naphthalen-2-yl]benzonitrile Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC=C(C=C2)C#N RHZYHLAACTZRAU-UHFFFAOYSA-N 0.000 description 1
- VUILGQFUZPFAGN-UHFFFAOYSA-N 4-[5-(1H-benzimidazol-2-yl)naphthalen-2-yl]phenol Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC=C(C=C2)O VUILGQFUZPFAGN-UHFFFAOYSA-N 0.000 description 1
- KKGLZDBABCCBFE-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)anilino]methyl]-2-(1H-imidazol-2-yl)benzoic acid Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)NCC2=CC(=C(C(=O)O)C=C2)C=2NC=CN2 KKGLZDBABCCBFE-UHFFFAOYSA-N 0.000 description 1
- KWGAFOAJUVRISO-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)anilino]methyl]benzonitrile Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)NCC2=CC=C(C=C2)C#N KWGAFOAJUVRISO-UHFFFAOYSA-N 0.000 description 1
- BZLUIYIRXQEYGJ-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]-2-(1H-imidazol-2-yl)benzoic acid Chemical compound N1=C(NC2=C1C=CC=C2)C=1C=C(C=CC=1)CNC1=CC(=C(C(=O)O)C=C1)C=1NC=CN=1 BZLUIYIRXQEYGJ-UHFFFAOYSA-N 0.000 description 1
- GWWQOSCXQNOPDN-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]-2-methoxybenzoic acid Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=C(C(=O)O)C=C2)OC GWWQOSCXQNOPDN-UHFFFAOYSA-N 0.000 description 1
- PYUYAYBOAMSTMM-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]-2-methoxybenzonitrile Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=C(C=C2)C#N)OC PYUYAYBOAMSTMM-UHFFFAOYSA-N 0.000 description 1
- LZKKMTLMMJJHTD-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]-2-methoxyphenol Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=C(C=C2)O)OC LZKKMTLMMJJHTD-UHFFFAOYSA-N 0.000 description 1
- YUSIDOIUUUGAIK-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]benzoic acid Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC=C(C(=O)O)C=C2 YUSIDOIUUUGAIK-UHFFFAOYSA-N 0.000 description 1
- HBBNIYZJHYEUBE-UHFFFAOYSA-N 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]benzonitrile Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC=C(C=C2)C#N HBBNIYZJHYEUBE-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- GOBHVZIVCCFNFK-UHFFFAOYSA-N 6-[3-(1H-benzimidazol-2-yl)phenyl]naphthalen-2-ol Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)C=2C=C1C=CC(=CC1=CC2)O GOBHVZIVCCFNFK-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100040104 DNA-directed RNA polymerase III subunit RPC9 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101001104144 Homo sapiens DNA-directed RNA polymerase III subunit RPC9 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- CWQWYENUNGVBCZ-UHFFFAOYSA-N N-[3-(1H-benzimidazol-2-yl)phenyl]-3-(1H-imidazol-2-yl)benzenesulfonamide Chemical compound N1=C(NC2=C1C=CC=C2)C=1C=C(C=CC=1)NS(=O)(=O)C1=CC(=CC=C1)C=1NC=CN=1 CWQWYENUNGVBCZ-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- XBWUQCAXTPMJFM-UHFFFAOYSA-N N-[[3-(1H-benzimidazol-2-yl)phenyl]methyl]-3,4,5-trimethoxyaniline Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=C(C(=C2)OC)OC)OC XBWUQCAXTPMJFM-UHFFFAOYSA-N 0.000 description 1
- UWXXNAQMIDFGTA-UHFFFAOYSA-N N-[[3-(1H-benzimidazol-2-yl)phenyl]methyl]-3,4-dimethoxyaniline Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=C(C=C2)OC)OC UWXXNAQMIDFGTA-UHFFFAOYSA-N 0.000 description 1
- QZPZGWGVHMMCCF-UHFFFAOYSA-N N-[[3-(1H-benzimidazol-2-yl)phenyl]methyl]-3-(1H-imidazol-2-yl)aniline Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=CC=C2)C=2NC=CN2 QZPZGWGVHMMCCF-UHFFFAOYSA-N 0.000 description 1
- MARWTIQEDCLEDW-UHFFFAOYSA-N N-[[3-(1H-benzimidazol-2-yl)phenyl]methyl]-4-(1H-imidazol-2-yl)aniline Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC=C(C=C2)C=2NC=CN2 MARWTIQEDCLEDW-UHFFFAOYSA-N 0.000 description 1
- XLBMYBZPGXPVPI-UHFFFAOYSA-N N-[[3-(1H-benzimidazol-2-yl)phenyl]methyl]-4-methoxyaniline Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC=C(C=C2)OC XLBMYBZPGXPVPI-UHFFFAOYSA-N 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- YBYPYIJRGCUJKM-UHFFFAOYSA-N N1=C(NC2=C1C=CC=C2)C=1C=C(C=CC=1)NC(=O)C1=CC(=C(C(=O)O)C=C1)C=1NC=CN=1 Chemical compound N1=C(NC2=C1C=CC=C2)C=1C=C(C=CC=1)NC(=O)C1=CC(=C(C(=O)O)C=C1)C=1NC=CN=1 YBYPYIJRGCUJKM-UHFFFAOYSA-N 0.000 description 1
- IIXMQLFPTPYJTK-UHFFFAOYSA-N N1=C(NC2=C1C=CC=C2)C=1C=C(C=CC=1)NS(=O)(=O)C1=CC(=C(C=C1)O)OC Chemical compound N1=C(NC2=C1C=CC=C2)C=1C=C(C=CC=1)NS(=O)(=O)C1=CC(=C(C=C1)O)OC IIXMQLFPTPYJTK-UHFFFAOYSA-N 0.000 description 1
- RBSXBEKBTPJAGP-UHFFFAOYSA-N N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=C(C=C2)C=2NC=CN2)OC Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=C(C=C2)C=2NC=CN2)OC RBSXBEKBTPJAGP-UHFFFAOYSA-N 0.000 description 1
- SKMNCTKBVXOHSL-UHFFFAOYSA-N N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)NC(=O)C2=CC=C(C=C2)O Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)NC(=O)C2=CC=C(C=C2)O SKMNCTKBVXOHSL-UHFFFAOYSA-N 0.000 description 1
- FXENOTAQSMFYMM-UHFFFAOYSA-N N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)NS(=O)(=O)C2=CC(=C(C(=C2)OC)OC)OC Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)NS(=O)(=O)C2=CC(=C(C(=C2)OC)OC)OC FXENOTAQSMFYMM-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- KDPQTPZDVJHMET-XSYGEPLQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)C)=CC=C3[C@H]21 KDPQTPZDVJHMET-XSYGEPLQSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- NXQOQNROJJFYCJ-FZFXZXLVSA-N androst-16-ene Chemical group C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC21 NXQOQNROJJFYCJ-FZFXZXLVSA-N 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N androstane group Chemical group [C@@H]12CCC[C@@]1(C)CC[C@H]1[C@H]2CC[C@H]2CCCC[C@]12C QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- KDJVUTSOHYQCDQ-UHFFFAOYSA-N carbamic acid;1h-imidazole Chemical compound NC([O-])=O.[NH2+]1C=CN=C1 KDJVUTSOHYQCDQ-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 150000002167 estrones Chemical class 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical class IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 150000008424 iodobenzenes Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- JSGLLPRBCSONSP-UHFFFAOYSA-N methyl 4-[5-(1H-benzimidazol-2-yl)naphthalen-2-yl]-2-methoxybenzoate Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC(=C(C(=O)OC)C=C2)OC JSGLLPRBCSONSP-UHFFFAOYSA-N 0.000 description 1
- DBKCEXKUAUIJFR-UHFFFAOYSA-N methyl 4-[5-(1H-benzimidazol-2-yl)naphthalen-2-yl]benzoate Chemical compound N1=C(NC2=C1C=CC=C2)C2=C1C=CC(=CC1=CC=C2)C2=CC=C(C(=O)OC)C=C2 DBKCEXKUAUIJFR-UHFFFAOYSA-N 0.000 description 1
- UINYYBBPOWHRBL-UHFFFAOYSA-N methyl 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]-2-methoxybenzoate Chemical compound N1=C(NC2=C1C=CC=C2)C=2C=C(C=CC2)CNC2=CC(=C(C(=O)OC)C=C2)OC UINYYBBPOWHRBL-UHFFFAOYSA-N 0.000 description 1
- NPUBXRHMMUQOBS-UHFFFAOYSA-N methyl 4-[[3-(1H-benzimidazol-2-yl)phenyl]methylamino]benzoate Chemical compound COC(=O)C1=CC=C(NCC2=CC(=CC=C2)C2=NC3=CC=CC=C3N2)C=C1 NPUBXRHMMUQOBS-UHFFFAOYSA-N 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- CBMSDILKECEMOT-UHFFFAOYSA-N potassium;2-methylpropan-1-olate Chemical compound [K+].CC(C)C[O-] CBMSDILKECEMOT-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- OZZAYJQNMKMUSD-DMISRAGPSA-N pregnenolone succinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 OZZAYJQNMKMUSD-DMISRAGPSA-N 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808345P | 2013-04-04 | 2013-04-04 | |
| US61/808,345 | 2013-04-04 | ||
| US201361808902P | 2013-04-05 | 2013-04-05 | |
| US61/808,902 | 2013-04-05 | ||
| PCT/US2014/033063 WO2014165815A2 (en) | 2013-04-04 | 2014-04-04 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2014247941A1 AU2014247941A1 (en) | 2015-10-22 |
| AU2014247941B2 AU2014247941B2 (en) | 2017-04-27 |
| AU2014247941C1 true AU2014247941C1 (en) | 2019-10-31 |
Family
ID=51659362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014247941A Active AU2014247941C1 (en) | 2013-04-04 | 2014-04-04 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9694005B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3514147B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6417392B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014247941C1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3151555A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014165815A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3200801B1 (en) | 2014-10-02 | 2024-04-24 | University of Maryland, Baltimore | Methods of treating pancreatic cancer |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
| EP3474848A4 (en) * | 2016-06-22 | 2020-04-15 | University of Maryland, Baltimore | PROCESS FOR PRODUCING NEW GALETERONE ANALOGS AND USES THEREOF |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| CN106902112B (zh) * | 2017-03-07 | 2019-06-04 | 中国医学科学院医药生物技术研究所 | Imb-a6作为雄激素受体拮抗剂的应用 |
| CN111943889B (zh) * | 2020-07-24 | 2022-07-22 | 中国医学科学院医药生物技术研究所 | 一种双芳香基胺类化合物及其制备方法和应用 |
| CN116444599A (zh) * | 2022-01-07 | 2023-07-18 | 中国科学院上海药物研究所 | 甾体类化合物及制备方法和用途 |
| WO2024064026A1 (en) * | 2022-09-19 | 2024-03-28 | Alterome Therapeutics, Inc. | Akt1 modulators |
| IL319572A (en) * | 2022-09-26 | 2025-05-01 | Alterome Therapeutics Inc | AKT1 modulators |
| EP4608841A1 (en) * | 2022-10-25 | 2025-09-03 | University of Maryland, Baltimore | Salts of galeterone and salts of next generation galeterone analogs, and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360809A (en) * | 1992-03-26 | 1994-11-01 | Neurosearch A/S | Imidazole compounds and their use as calcium channel blockers |
| US5541229A (en) * | 1989-04-08 | 1996-07-30 | Dr. Karl Thomae Gmbh | Benzimidazoles and medicaments containing these compounds |
| US20100048913A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA129379A (en) | 1910-10-18 | 1910-11-22 | John Clarence Bisland | Hoe |
| IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
| DE10342503A1 (de) * | 2003-09-12 | 2005-04-14 | Merck Patent Gmbh | Benzyl-Benzimidazolylderivate |
| PT2206719E (pt) | 2005-03-02 | 2015-02-05 | Univ Maryland | Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno |
| CN101990433B (zh) * | 2008-02-07 | 2014-11-05 | 马萨诸塞眼科耳科诊所 | 提高Atoh1表达的化合物 |
| US20110118219A1 (en) * | 2008-03-25 | 2011-05-19 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
| BRPI1008745A2 (pt) * | 2009-02-05 | 2019-09-17 | Tokai Pharmaceuticals Inc | pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios |
| US20110319369A1 (en) * | 2009-02-05 | 2011-12-29 | Tokai Pharmaceuticals, Inc. | Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent |
| JP2014523445A (ja) * | 2011-07-18 | 2014-09-11 | トーカイ ファーマシューティカルズ，インク． | 前立腺癌を処置するための新規な組成物及び方法 |
| CN105682662A (zh) * | 2013-03-14 | 2016-06-15 | 马里兰大学巴尔的摩校区 | 雄激素受体减量调节剂及其用途 |
-
2014
- 2014-04-04 CA CA3151555A patent/CA3151555A1/en active Pending
- 2014-04-04 CA CA2908577A patent/CA2908577C/en active Active
- 2014-04-04 EP EP19161938.6A patent/EP3514147B1/en active Active
- 2014-04-04 WO PCT/US2014/033063 patent/WO2014165815A2/en not_active Ceased
- 2014-04-04 EP EP14779540.5A patent/EP2991644B1/en active Active
- 2014-04-04 US US14/781,437 patent/US9694005B2/en active Active
- 2014-04-04 JP JP2016506667A patent/JP6417392B2/ja active Active
- 2014-04-04 AU AU2014247941A patent/AU2014247941C1/en active Active
-
2017
- 2017-05-31 US US15/609,803 patent/US10617685B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541229A (en) * | 1989-04-08 | 1996-07-30 | Dr. Karl Thomae Gmbh | Benzimidazoles and medicaments containing these compounds |
| US5360809A (en) * | 1992-03-26 | 1994-11-01 | Neurosearch A/S | Imidazole compounds and their use as calcium channel blockers |
| US20100048913A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014165815A2 (en) | 2014-10-09 |
| US20160038476A1 (en) | 2016-02-11 |
| CA3151555A1 (en) | 2014-10-09 |
| CA2908577C (en) | 2022-05-31 |
| EP3514147B1 (en) | 2022-08-03 |
| CA2908577A1 (en) | 2014-10-09 |
| WO2014165815A3 (en) | 2014-12-31 |
| JP6417392B2 (ja) | 2018-11-07 |
| JP2016515630A (ja) | 2016-05-30 |
| US9694005B2 (en) | 2017-07-04 |
| EP2991644A2 (en) | 2016-03-09 |
| EP2991644A4 (en) | 2017-02-08 |
| US10617685B2 (en) | 2020-04-14 |
| US20170266181A1 (en) | 2017-09-21 |
| EP2991644B1 (en) | 2020-03-25 |
| EP3514147A1 (en) | 2019-07-24 |
| AU2014247941A1 (en) | 2015-10-22 |
| AU2014247941B2 (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014247941C1 (en) | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | |
| US9884067B2 (en) | Androgen receptor down-regulating agents and uses thereof | |
| SK112893A3 (en) | Benzofuran derivatives, method of their preparation and pharmaceutical compositions containing them | |
| US12162818B2 (en) | Inhibitors of the n-terminal domain of the androgen receptor | |
| EP1723105B1 (en) | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | |
| CA2978454A1 (en) | Altering steroid metabolism for treatment of steroid-dependent disease | |
| WO2010060214A1 (en) | Hybrid -ionone and curcumin molecules as anticancer agents | |
| IL179437A (en) | Benzimidazol-2-ylidene propane-1,3-dione derivatives and pharmaceutical compositions thereof | |
| US20150148321A1 (en) | Substituted androst-4-ene diones | |
| WO2018175965A1 (en) | Antiestrogens for cancer therapy | |
| EP2802563B1 (en) | Novel heteroarylamide derivatives having antiandrogenic properties | |
| HK1201838B (en) | Novel heteroarylamide derivatives having antiandrogenic properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: UNIVERSITY OF MARYLAND, BALTIMORE Free format text: FORMER APPLICANT(S): UNIVERSITY OF MARYLAND, BALTIMORE; PURUSHOTTAMACHAR, PURANIK; NJAR, VINCENT |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 JUL 2019 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 JUL 2019 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ NJAR, VINCENT C.O. AND PURANIK, PURUSHOTTAMACHAR |